Overview

Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)

Status:
Completed
Trial end date:
1997-03-01
Target enrollment:
Participant gender:
Summary
To determine whether hydroxyurea prevents the onset of chronic end organ damage in young children with sickle cell anemia.
Phase:
Phase 2
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Hydroxyurea